Case description: A 42 year old lady who originally presented aged 32 with fevers, fatigue and cervical lymphadenopathy. Lymph node biopsy demonstrated a necrotising lymphadenitis consistent with Kikuchi's disease. She received symptomatic treatment and her symptoms resolved. Aged 37 she developed lymphadenopathy, fever, malaise as well as a scaly erythematous rash initially affecting her cheeks but then spreading to involve her chest and upper arms. In addition, she was experiencing generalised joint pains, morning stiffness, a low-grade fever and alopecia. Initial investigations showed pancytopenia with a raised ESR, positive ANA (1:160) and anti-dsDNA antibodies (149IU/ml), positive anti-Ro, anti-RNP and anti-SM antibodies based on which she was diagnosed with SLE. She was commenced on treatment with a reducing dose regimen of prednisolone as well as hydroxychloroquine 200mg twice a day with significant improvement in her symptoms. On reducing the prednisolone doseshefound hersymptoms worsened,particularly with regards to joint pains and rash. She was therefore commenced on treatment with azathioprine 50mg daily and remained well. She was keen to reduce the amount of medication she was taking so stopped azathioprine. She was admitted to hospital in December 2017 with right sided neck and jaw pain along with swelling over the parotid region. Ultrasound examination findings revealed bilateralparotitis. She was treated with clindamycin for suspected infective parotitis and her symptoms resolved. A week later she developed an erythematous scaly rash, initially affecting her face but then spread to cover her whole body. Histological findings of the skin biopsy were suggestive of a drug rash. However, laboratory parameters revealed elevated anti-dsDNA antibodies (276IU/ml) and low complement (C3 0.47 g/L, C4 0.08 g/L). Taken together, these findings were indicative of a flare up of SLE. Hence, she was treated with a higher dose of oral prednisolone of 40mg/day concomitantly with a dose of intravenous Methylprednisolone 500mg attaining good response. In early 2018 she became more unwell with recurrence of the rash, lethargy, back pain, nausea and worsening parotid pain. Blood tests showed pancytopenia (WCC 3.1, platelets 131, haemoglobin 87d/L), with a raised LDH (592U/L), Ferritin 3300 ug/L, triglycerides 3.81mmol/L. CT of chest, abdomen and pelvis revealed no lymphadenopathy. A bone marrow trephine biopsy demonstrated atypical/dysplastic features and haemophagocytosis. Collectively, these findings were indicative of macrophage activation syndrome and she was treated with a single dose of intravenous methylprednisolone 1g and commenced on mycophenolate mofetil 1g twice a day with reducing dose regimen of oral prednisolone. She was monitored frequently for signs of flare up of lupus and to evaluate for MAS. Laboratory parameters were also measured daily for a week and subsequently, weekly. There was a significant improvement in her symptoms consistently. Over a period of five weeks, the laboratory markers including ferritin, LDH, white cell count, platelets and haemoglobin normalised. At six months since concurrent diagnosis of MAS and lupus flare, she remains well on a combination of mycophenolate 1g twice daily and oral prednisolone of 10 mg/day. Discussion: Concurrent MAS and flare up of lupus has been previously described and MAS may be the presenting feature of SLE. However, clini
cal features and laboratory indices may not clearly distinguish lupus flare from MAS, which is associated with high mortality. Therefore, a combination of potent immunosuppressants is used to treat concurrent MAS and lupus flare. In our patient with SLE described here, a high index of suspicion of MAS led us to obtain appropriate investigations without delay. Thus, securing an early diagnosis and treatment. We hypothesised that active lupus manifesting in skin and parotid glands was triggered by T cell infiltration and seemed to respond favourably to relatively low dose corticosteroid therapy. Ciclosporin and other immunosuppressive agents such as etoposide, cyclophosphamide, rituximab and plasma exchange have been used effectively to treat MAS in the context of Lupus. Treatment with ciclosporin is associated with significant adverse effect profile. Therefore, alternative immunosuppressive regimen with mycophenolate was considered in combination with low to moderate dose of oral corticosteroids. We monitored the clinical features and laboratory parameters regularly. We used the trend of changes in laboratory parameters to guide treatment decisions. As previously reported, we found that it may take weeks for the laboratory parameters to normalise whereas the trend of the kinetics of biochemical parameters was evident at shorter time interval and is likely influenced by the activation status of macrophages perhaps reflecting their role in lipid metabolism. Over a period of five weeks from the first dose of IVMP and mycophenolate, we noted significant improvement in clinical symptoms, signs and normalisation of laboratory parameters, sustained at six months follow-up. To our knowledge, there exists only one previous case report where mycophenolate alone in combination with relatively modest dose of corticosteroids has been used to treat MAS in apatient with lupus. Introduction: Systemic lupus erythematosus (SLE) and primary sclerosing cholangitis (PSC) are both uncommon conditions, with SLE having an estimated incidence of 1 to 10 per 100,000 person-years with female:-male ratio of 8-15:1, whilst PSC occurs more rarely with an estimated incidence rate of 0.77 per 100,000 person-years and an incidence rate ratio for males versus females of 1.70 (1.34-2.07). Despite the rarity of the two conditionsand the improbability of them coexisting in the same patient by chance, we report the coexistence of SLE and sclerosing cholangitis in a patient, who responded well to ursodeoxycholic acid. Case description: We report the case of a 56 year old female patient with a history of SLE and anti-phospholipid syndrome since 18 years and 31 years of age respectively, who now presented with a one week history of worsening generalised abdominal pain. She had experienced similar episodes previously. Her past medical history included an episode of amaurosis fugax at age 31, right adrenal haemorrhage in 2011 that had rendered her dependent on steroids and arteritis of the left common and internal iliac arteries, which was confirmed on PET CT in 2015. She had also been investigated in view of a history of deranged liver function tests (LFT). At time of admission, she was taking prednisolone 10mg daily. Hydroxychloroquine had been tried unsuccessfully in the past but had been stopped due to severe intolerance, and she had been reluctant to start other disease-modifying agents to control her lupus activity. On presentation,shewashaemodynamicallystable andafebrile. Clinicalexamination was normal other than the presence of a malar rash, with her abdomen being soft and non-tender. She had a normal white count of 9, lymphocyte count of 1.04x10^9/L, haemoglobin of 9.7g/dL, MCV of 93fL and platelet count of 187 x10^9/L.. Erythrocyte sedimentation rate was moderately elevated at 56 mm/ 1stHr but the C-reactive protein was normal at 4.4mg/L.Liver function tests included a minimally raised bilirubin of 26.6umol/L, and alanine aminotransferase of 39U/L, whilst gammaglutamyl transferase and alkaline phosphatase were moderately raised at 303U/L and 257U/L respectively. Renal profile and amylase were normal. A computed tomography (CT) scan of the abdomen demonstrated mildy dilated intrahepatic bileducts with a normal calibre common bile duct (6-7mm). There were no focal lesions in the liver and spleen. Small gallbladder stones were noted. The rest of the scan was normal. Further characterisation on magnetic resonance cholangiopancreaticography (MRCP) was consistent with a sclerosing cholangiopathy with multiple strictures, predominantly involving the right hepatic duct and its main branches, as well as the left hepatic duct and the segment II and III branches. Mild intrahepatic dilatation was noted secondary to the presence of the strictures, together with the presence of multiple cast calculi within these dilated ducts which were T1 hyperintense. There was no involvement of the extrahepatic biliary tree and the junction between the common bile duct and the pancreatic duct was normal. Gallstones were seen within the gallbladder with no signs of cholecystitis and no evidence of choledocholithiasis. There was no evidence of cirrhosis. The spleen was normal in size, and no focal liver lesions were identified. Comparison was made to the MRCP that had been performed two years earlier in December 2015 during investigation for deranged liver function tests and it was noted that whilst gallbladder stones were present, there had been no evidence of intrahepatic or extrahepatic biliary dilatation at this point. An oesophago-gastro-duodenoscopy at the time had not shown any pathology. Although a liver biopsy and colonoscopy had been offered to the patient, she had at the time declined, and also failed to attend for further investigation and follow up.In view of the new MRCP findings of sclerosing cholangitis, she was started on ursodeoxycholic acid (UDCA) 750mg daily, with marked improvement in the liver function tests as shown in the table below. Azathioprine was subsequently introduced in March 2018 as a steroid sparing agent, but this had to be stopped as shortly after its introduction the patient developed lethargy, nausea and severe bruising which settled oncessationof the azathioprine. Discussion: The liver may be affected by a wide variety of rheumatic diseases, and dysfunction may be due to the toxic effects of pharmacotherapy or related to the autoimmune disease. Liver dysfunction may also occur as a primary disorder in association with rheumatic disease. Abnormality of hepatic function in association with SLE has been described as early as 1955 and is reported in as many as 25-50% of patients with lupus. In most cases, this is only subclinical and end stage liver disease israreinSLE.The liver-relatedcomplications inSLE includes lupus hepatitis as well as autoimmune liver diseases such as autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis (PSC). Steatohepatitis, fatty liver and drug-induced liver injury may also occur. Distinguishing between them is often challenging. To date, few literature reviews and case reports of concomitant PSC and SLE have been published. Although a liver biopsy is diagnostic of PSC by the presence of typical onion-skinning appearance and periductal inflammation, diagnosis is nowadays established with non-invasive imaging study, typically, an MRCP as was done in this patient. Possible associations between PSC and SLEhave been noted inthe literature. Themost common genetic findings in primary sclerosing cholangitis have been identified within the HLA complex on chromosome 6 with an odds ration of 3-5. However, in a comprehensive review article, it was demonstrated how candidate genes outside of this complex have been reported in both PSC and a number of auto-immune diseases based on mapping of genome-wide significant riskloci. Twenty three genome-wide significant (p 10-8) riskloci outside of the HLA complex on chromosome 6 have been reported together with the associated candidate genes, and the P value for the single nucleotide polymorphism within this implicated risk region in PSC. Of relevance to this case, an association has been made between the candidate genes for both PBC and SLE. These genes include SH2B3 and ATXN2 on chromosome 12q24 and CLEC16A and SOCS1 on chromosome 16q12. Thus, this might prove that there is common genetic susceptibility towards developing both SLE and PSC. Key Learning Points: It is still unclear whether PSC occurring in relation to SLE is coincidental or if there is a casual association between the two conditions. More research inthisfieldmayyield moreclues about thepossible genetic link between these two diseases. Disclosure: M. Camilleri: None. Z. Gauci: None. K. Cassar: None. P. Cassar: None. 
